MiR-9 is a tumor suppressor in pediatric AML with t(8;21)

Leukemia

Volumn 28, Issue 5, 2014, Pages 1022-1032

  Emmrich, S ^a   Katsman Kuipers, J E ^b   Henke, K ^a   Khatib, M E ^a   Jammal, R ^a   Engeland, F ^a   Dasci, F ^a   Zwaan, C M ^b   Den Boer, M L ^b   Verboon, L ^b   Stary, J ^c   Baruchel, A ^d   De Haas, V ^e   Danen Van Oorschot, A A ^b   Fornerod, M ^b   Pieters, R ^b   Reinhardt, D ^a   Klusmann, J H ^a   Van Den Heuvel Eibrink, M M ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^d SAINT LOUIS HOSPITAL   (France)

^e Dutch Childhood Oncology Group DCOG   (Netherlands)

Author keywords

AML1 ETO; HMGA2; LIN28B; microRNA; miR 9; t(8; 21)

Indexed keywords

COLECALCIFEROL; MICRORNA; MICRORNA 9; MIXED LINEAGE LEUKEMIA PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS ASSAY; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION ASSAY; CELL SELECTION; CELL VIABILITY ASSAY; CFU COUNTING; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOGENETICS; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; KARYOTYPE; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MOUSE; NONHUMAN; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; WESTERN BLOTTING; XENOTRANSPLANTATION;

ANIMALS; CELL DIVISION; CHILD; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; FLOW CYTOMETRY; GENES, TUMOR SUPPRESSOR; HETEROGRAFTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, NUDE; MICRORNAS; TRANSLOCATION, GENETIC;

EID: 84899960011     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.357     Document Type: Article

References (53)

1. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E. et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. Blood 2012; 120: 3187-3205.
2. Balgobind BV, Hollink IHIM, Arentsen-Peters STCJM, Zimmermann M, Harbott J, Beverloo B. et al. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica 2011; 96: 1478-1487.
3. Doöhner H, Estey EH, Amadori S, Appelbaum FR, Buöchner T, Burnett AK. et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
4. Zhang L, Sankaran VG, Lodish HF. MicroRNAs in erythroid and megakaryocytic differentiation and megakaryocyte-erythroid progenitor lineage commitment. Leukemia 2012; 26: 2310-2316.
5. Bartel DP, Chen C-Z. Micromanagers of gene expression: The potentially widespread influence of metazoan microRNAs. Nat Rev Genet 2004; 5: 396-400.
6. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A. et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res 2010; 20: 589-599.
7. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJM, Lowenberg B, Löwenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008; 111: 5078-5085.
8. Maki K, Yamagata T, Sugita F, Nakamura Y, Sasaki K, Mitani K. Aberrant expression of MIR9 indicates poor prognosis in acute myeloid leukaemia. Br J Haematol 2012; 158: 283-285.
9. Sun SM, Rockova V, Bullinger L, Dijkstra MK, Doöhner H, Löwenberg B. et al. The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia 2013; 27: 100-106.
10. Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D. et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 5257-5264.
11. Oorschot AAD, Kuipers JE, Arentsen-peters S, Schotte D, Reinhardt D, De Haas V. et al. Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Pediatr Blood Cancer 2011; 2: 1-7.
12. Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ. et al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 2009; 113: 3314-3322.
13. Batliner J, Buehrer E, Federzoni EA, Jenal M, Tobler A, Torbett BE. et al. Transcriptional regulation of MIR29B by PU.1 (SPI1) and MYC during neutrophil differentiation of acute promyelocytic leukaemia cells. Br J Haematol 2012; 157: 270-274.
14. Klusmann JH, Li Z, Böhmer K, Maroz A, Koch ML, Emmrich S. et al. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev 2010; 24: 478-490.
15. Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R. et al. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-Targeting approach in acute myeloid leukemia. Leukemia 2013; 27: 871-878.
16. Bai H, Cao Z, Deng C, Zhou L, Wang C. miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. J Cancer Res Clin Oncol 2012; 138: 595-602.
17. Kaspers GJ, Veerman AJ, Pieters R, Broekema GJ, Huismans DR, Kazemier KM. et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-Thiazol-Tetrazolium assay. Br J Cancer 1994; 70: 1047-1052.
18. Stankov MV, El Khatib M, Kumar Thakur B, Heitmann K, Panayotova-Dimitrova D, Schoening J. et al. Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia 2014; 28: 577-588.
19. Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, Buijs-Gladdines J. et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood 2006; 108: 3520-3529.
20. Emmrich S, Henke K, Hegermann J, Ochs M, Reinhardt D, Klusmann JH. miRNAs can increase the efficiency of ex vivo platelet generation. Ann Hematol 2012; 91: 1673-1684.
21. Loya CM, Lu CS, Van Vactor D, Fulga TA. Transgenic microRNA inhibition with spatiotemporal specificity in intact organisms. Nat Methods 2009; 6: 897-903.
22. Maetzig T, Galla M, Brugman MH, Loew R, Baum C, Schambach A. Mechanisms controlling titer and expression of bidirectional lentiviral and gammaretroviral vectors. Gene Ther 2010; 17: 400-411.
23. Klusmann JH, Godinho FJ, Heitmann K, Maroz A, Koch ML, Reinhardt D. et al. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev 2010; 24: 1659-1672.
24. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2011.
25. Smyth GK. Linear models and emperical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: 1-25.
26. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: An integrated resource for microRNA-Target interactions. Nucleic Acids Res 2009; 37: D105-D110.
27. Wang X. miRDB: A microRNA target prediction and functional annotation database with a wiki interface. RNA 2008; 14: 1012-1017.
28. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet 2007; 39: 1278-1284.
29. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
30. Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S. et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood 2012; 119: 2314-2324.
31. Petriv OI, Kuchenbauer F, Delaney AD, Lecault V, White A, Kent D. et al. Comprehensive microRNA expression profiling of the hematopoietic hierarchy. PNAS 2010; 107: 15443-15448.
32. Hegde SP, Zhao J, Ashmun RA, Shapiro LH. c-Maf induces monocytic differentiation and apoptosis in bipotent myeloid progenitors. Blood 1999; 94: 1578-1589.
33. Aziz A, Soucie E, Sarrazin S, Sieweke MH. MafB/c-Maf deficiency enables selfrenewal of differentiated functional macrophages. Science 2009; 326: 867-871.
34. Yuan J, Nguyen CK, Liu X, Kanellopoulou C, Muljo SA. Lin28b reprograms adult bone marrow hematopoietic progenitors to mediate fetal-like lymphopoiesis. Science 2012; 335: 1195-1200.
35. Odero MD, Grand FH, Iqbal S, Ross F, Roman JP, Vizmanos JL. et al. Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. Leukemia 2005; 19: 245-252.
36. Piskounova E, Polytarchou C, Thornton JE, Hagan JP, Lapierre J, Pothoulakis C. et al. Oncogenic Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 2012; 147: 730-748.
37. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A. et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-647.
38. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007; 21: 1025-1030.
39. Senyuk V, Zhang Y, Liu Y, Ming M, Premanand K, Zhou L. et al. Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis. P Natl Acad Sci USA 2013; 110: 5594-5599.
40. Lin X, Rice KL, Buzzai M, Hexner E, Costa FF, Kilpivaara O. et al. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia 2013; 27: 344-352.
41. Forrest ARR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N, Takahashi Y. et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 2010; 24: 460-466.
42. Mann G, Reinhardt D, Ritter J, Hermann J, Schmitt K, Gadner H. et al. Treatment with all-Trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 2001; 80: 417-422.
43. Chen P, Price C, Li Z, Li Y, Cao D, Wiley A. et al. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. P Natl Acad Sci USA 2013; 110: 11511-11516.
44. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
45. Heo I, Joo C, Cho J, Ha M, Han J, Kim VN. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol Cell 2008; 32: 276-284.
46. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin-28. Science 2008; 320: 97-100.
47. Rybak A, Fuchs H, Smirnova L, Brandt C, Pohl EE, Nitsch R. et al. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol 2008; 10: 987-993.
48. Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 2008; 14: 1539-1549.
49. Buössing I, Slack FJ, Grosshans H. let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 2008; 14: 400-409.
50. Tessari M, Gostissa M, Altamura S, Sgarra R, Rusthigh A, Salvagno C. et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol 2003; 23: 9104-9116.
51. Fedele M, Battista S, Kenyon L. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002; 21: 3190-3198.
52. Schoenmakers E, Wanschura S, Mols R, Bullerdiek J, Berghe H Van den, Ven WJM Van de. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nature 1995; 10: 436-444.
53. Mayr C, Hemann M, Bartel D. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007; 315: 1576-1579.